CharlesStewartLandisMD

Gastroenterology • Seattle, WA

Hepatology & Liver Transplantation

Assistant Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Landis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Landis' full profile

Already have an account?

Office
125 16th Ave E
Seattle, WA 98112
Phone+1 206-326-3000

Fax+1 877-515-2975

Education & Training

University of WashingtonFellowship, Transplant Hepatology, 2009 - 2010
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Gastroenterology, 2006 - 2009
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2002 - 2004
State University of New York Downstate Medical Center College of MedicineClass of 2002

Certifications & Licensure

WA State Medical License 2009 - 2025
NY State Medical License 2005 - 2020
American Board of Obesity Medicine Obesity Medicine

Clinical Trials

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Start of enrollment: 2011 Oct 01
Completed
Phase 2
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure Start of enrollment: 2013 Feb 01
Completed
Phase 3
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2013 Aug 01
Completed
Phase 2
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing Start of enrollment: 2014 Feb 01
Completed
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Completed
Phase 2
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 Start of enrollment: 2016 Jul 31
Withdrawn
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.
Aldo J Montano-Loza, Ellina Lytvyak, Gideon Hirschfield, Bettina E Hansen, Maryam Ebadi
Journal of Hepatology. 2024-10-01
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.
Cynthia Levy, Stephen Caldwell, Parvez Mantry, Velimir Luketic, Charles S Landis
Clinical and Translational Gastroenterology. 2024-08-01
Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.
Fanpu Ji, Sally Tran, Eiichi Ogawa, Chung-Feng Huang, Takanori Suzuki
Journal of Clinical and Translational Hepatology. 2024-07-28

Journal Articles

Can We Mitigate the Effects of Simultaneous Liver‐Kidney Transplantation Through Increased Utilization of HCV Positive Donors?
C K Johnson, J D Perkins, C S Landis, L Sibulesky, American journal of transplantation